Background/Aims: Eradication of early Barrett’s neoplasia by endoscopic resection and radiofrequency ablation is safe and effective. In T1b adenocarcinoma, standard of care remains controversial. We investigated the therapeutic outcome between high-grade dysplasia (HGD)/mucosal adenocarcinoma and submucosal adenocarcinoma in Barrett’s patients. We hypothesised similar outcome in low-risk (LR) T1b compared to T1a/HGD. Methods: Patients with endoscopically treated Barrett’s esophagus were included in a Swiss tertiary center cohort study. Primary outcome parameter was complete eradication of early neoplasia. Secondary outcome parameters were recurrence-free survival and safety of endoscopic treatment. Results: Forty-eight patients (1 female) with median Barrett’s length C4M6 and mean age of 66 years were included. Complete endoscopic eradication of HGD/T1a was achieved in 33 out of 35 and in 11 out of 13 T1b adenocarcinoma. During a median follow-up of 41 (interquartile range 28–63) months no systemic recurrence was observed in endoscopically treated HGD/T1a and LR -T1b and one in a high-risk T1b adenocarcinoma after surgery. Local recurrences were amenable to surgical or endoscopic re-treatment. No lymphnode metastasis was detected in initial staging with esophageal endosonography/positron emission tomography-CT. Conclusion: Comparable endoscopic eradication and recurrence rate were observed in HGD/T1a and LR T1b adenocarcinoma. Carefully selected LR T1b cancer may receive endoscopic treatment in an expert center without any negative impact on recurrence.

Journal Section:
Original Paper
Keywords:
Barrett’s esophagus, Submucosal cancer, Early adenocarcinoma, T1b adenocarcinoma, T1a adenocarcinoma, Endoscopic mucosal resection, Radiofrequency ablation, Combined endoscopic resection, Dysplasia
1.
Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142–146.
2.
van Sandick JW, van Lanschot JJ, ten Kate FJ, et al: Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction: implications for therapeutic decision making. Cancer 2000; 88: 2429–2437.
3.
Phoa KN, Pouw RE, Bisschops R, et al: Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2016; 65: 555–562.
4.
Runge TM, Abrams JA, Shaheen NJ: Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 2015; 44: 203–231.
5.
Pouw RE, Gondrie JJ, Sondermeijer CM, et al: Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008; 12: 1627–1636.
6.
Pouw RE, Bergman JJ: Radiofrequency ablation for Barrett’s esophagus, for whom and by whom? Clin Gastroenterol Hepatol 2013; 11: 1256–1258.
7.
Weusten B, Bisschops R, Coron E, et al: Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191–198.
8.
Westerterp M, Koppert LB, Buskens CJ, et al: Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Archiv 2005; 446: 497–504.
9.
Schölvinck D, Kunzli H, Meijer S, et al: Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease. Surg Endosc 2016; 30: 4102–4113.
10.
Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al: Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42: 1030–1036.
11.
Manner H, Pech O, Heldmann Y, et al: The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc 2015; 29: 1888–1896.
12.
Manner H, Wetzka J, May A, et al: Early-stage adenocarcinoma of the esophagus with mid to deep submucosal invasion (pT1b sm2–3): the frequency of lymph-node metastasis depends on macroscopic and histological risk patterns. Dis Esophagus 2017; 30: 1–11.
13.
Fotis D, Doukas M, Wijnhoven BP, et al: Submucosal invasion and risk of lymph node invasion in early Barrett’s cancer: potential impact of different classification systems on patient management. United European Gastroenterol J 2015; 3: 505–513.
14.
Pech O, Gunter E, Dusemund F, Origer J, Lorenz D, Ell C: Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010; 42: 456–461.
15.
Manner H, Pech O: Measurement of the tumor invasion depth into the submucosa in early adenocarcinoma of the esophagus (pT1b): can microns be the new standard for the endoscopist? United European Gastroenterol J 2015; 3: 501–504.
16.
Braghetto I, Csendes A, Cardemil G, Burdiles P, Korn O, Valladares H: Open transthoracic or transhiatal esophagectomy versus minimally invasive esophagectomy in terms of morbidity, mortality and survival. Surg Endosc 2006; 20: 1681–1686.
17.
Holscher AH, Vallbohmer D, Bollschweiler E: Early Barrett's carcinoma of the esophagus. Ann Thorac Cardiovasc Surg 2008; 14: 347–354.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.